CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $76,301 | -26.3% | 1,681 | -8.8% | 0.05% | -24.6% |
Q2 2023 | $103,522 | +13.5% | 1,844 | -8.6% | 0.06% | +22.0% |
Q1 2023 | $91,229 | -19.6% | 2,017 | -27.7% | 0.05% | -15.3% |
Q4 2022 | $113,454 | -3.0% | 2,791 | +55.5% | 0.06% | +25.5% |
Q3 2022 | $117,000 | +8.3% | 1,795 | +0.6% | 0.05% | +17.5% |
Q2 2022 | $108,000 | -17.6% | 1,784 | -14.3% | 0.04% | -32.2% |
Q1 2022 | $131,000 | -21.6% | 2,081 | -5.5% | 0.06% | -6.3% |
Q4 2021 | $167,000 | -9.2% | 2,203 | +34.0% | 0.06% | -22.2% |
Q3 2021 | $184,000 | -34.5% | 1,644 | -5.4% | 0.08% | -30.2% |
Q2 2021 | $281,000 | +15.2% | 1,737 | -13.3% | 0.12% | +12.6% |
Q1 2021 | $244,000 | -18.9% | 2,003 | +1.9% | 0.10% | -17.6% |
Q4 2020 | $301,000 | -30.2% | 1,966 | -61.9% | 0.12% | -44.7% |
Q3 2020 | $431,000 | +0.5% | 5,155 | -11.8% | 0.23% | +11.3% |
Q2 2020 | $429,000 | +84.1% | 5,844 | +6.3% | 0.20% | +111.5% |
Q1 2020 | $233,000 | -39.3% | 5,497 | -12.8% | 0.10% | +52.4% |
Q4 2019 | $384,000 | – | 6,306 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |